A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta

European Journal of Neurology

Volumn 9, Issue 6, 2002, Pages 645-655

  Paolillo, A ^a   Pozzilli, Carlo ^a,d   Giugni, E ^a   Tomassini, V ^a   Gasperini, C ^c   Fiorelli, M ^a   Mainero, C ^a   Horsfield, M ^b   Galgani, S ^c   Bastianello, S ^a   Buttinelli, C ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d Department of Neurological Sciences ^*

Author keywords

Brain atrophy; Disability; Interferon beta treatment; Magnetic resonance imaging; Multiple sclerosis; Relapse rate

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; MITOXANTRONE; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; BRAIN ATROPHY; BRAIN INJURY; BRAIN SIZE; DISABILITY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; REMISSION; ATROPHY; BRAIN; DISABLED PERSON; PATHOLOGY; PATIENT; PROGNOSIS; TIME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ATROPHY; BRAIN; DISABLED PERSONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT DROPOUTS; PROGNOSIS; TIME FACTORS;

EID: 0036835959     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1331.2002.00476.x     Document Type: Article

References (38)

1. Brex PA, Ciccarelli O, O'Rjordan JI, Sailer M, Thompson AJ, Miller DH (2002). A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164.
2. Filippi M, Horsfield MA, Morrissey SP et al. (1994). Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635-641.
3. Fisher E, Rudick RA, Cutter G et al. (2000). Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Multiple Sclerosis 6:373-377.
4. Fox NC, Jenkins R, Leary M et al. (2000). Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 54:807-812.
5. Gasperini C, Pozzilli C, Bastianello S et al. (1999). Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion Volume on T1 weighted images. J Neurol Neurosurg Psychiatry 67:579-584.
6. Ge Y, Grossman RI, Udupa JK et al. (2000). Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 214:665-670.
7. Grimaud J, Lai M, Thorpe J et al. (1996). Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging 14:495-505.
8. IFNB Multiple Sclerosis Study Group University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized, controlled trial. Neurology 45:1277-1285.
9. IFNB Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661.
10. Jacobs LD, Cookfair DL, Rudick RA et al. (1996). Intra-muscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 39:285-294.
11. Jacobs L, Rudick R, Simon J (2000). Extended observations on MS patients treated with IM interferon-β-1a (Avonex™): implications for modern MS trials and therapeutics. J Neuroimmunol 107:167-173.
12. Kurtzke JF (1983). Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444-1452.
13. Li DK, Paty DW, UBC.MS/MRI Analysis Research Group, the PRISMS Study Group (1999). Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing-remitting multiple sclerosis. Ann Neurol 46:197-206.
14. Lin X, Blhumardt (2001). Inflammation and atrophy in multiple sclerosis MRI association with disease course. J Neurol Sci 189:99-104.
15. Losseff NA, Wang L, Lai HM et al. (1996). Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 19:2009-2019.
16. Miller DH, Grossman RI, Reingold SC, McFarland HF (1998). The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121:3-24.
17. Molyneux PD, Filippi M, Barkhof F et al. (1998). Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion Volume in multiple sclerosis. Ann Neurol 43:332-339.
18. Molyneux PD, Kappos L, Polman C et al. (2000). The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 123:2256-2263.
19. O'Riordan JI, Thompson AJ, Kingsley DP et al. (1998). The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A10-year follow-up. Brain 121:495-503.
20. Paolillo A, Coles AJ, Molyneux PD et al. (1999a). Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath IH. Neurology 11:751-757.
21. Paolillo A, Bastianello S, Frontoni M et al. (1999b). MR imaging outcome of new enhancing lesions in relapsing-remitting patients treated with recombinant interferon beta 1a. J Neurol 246:443-446.
22. Paolillo A, Pozzilli C, Gasperini C et al. (2000). Brain atrophy in relapsing-remitting multiple sclerosis: relationship with 'black holes', disease duration and clinical disability. J Neurol Sci 174:85-91.
23. Paty DW, Li DK (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43:662-667.
24. Pozzilli C, Bastianello S, Koudriavtseva T et al. (1996). Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61:251-258.
25. Pozzilli C, Koudriavtseva T (1997). Interferon beta-1a. Baillieres Clin Neurol 6:481-493.
26. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (1998). Randomised double-blind placebo-controlled study of Interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504.
27. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group (2001). PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 56:1628-1636.
28. Rovaris M, Inglese M, van Schijndel RA et al. (2000). Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 247:960-965.
29. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J (2000). Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS and treatment with interferon β-1a. Multiple Sclerosis 6:365-372.
30. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L and the Multiple Sclerosis Collaborative Research Group (1999). Use of the brain parenchimal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 53:1698-1704.
31. Sailer M, O'Riordan JI, Thompson AJ et al. (1999). Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 52:599-606.
32. Simon JH, Jacobs LD, Campion M (1998). Magnetic Resonance studies of intramuscular interferon β-1a for relapsing-remitting multiple sclerosis. Ann Neurol 43:79-87.
33. Simon JH, Jacobs LD, Campion MK et al. (1999). A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 53:139-148.
34. Simon JH, Lull J, Jacobs LD et al. (2000). A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 55:185-192.
35. Stone LA, Frank JA, Alberst PS et al. (1997). Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 49:862-869.
36. The Once Weekly Interferon for MS, Study Group (OWIMS) (1999). Evidence of interferon, β-1a dose-response in relapsing-remitting MS. Neurology 53:679-689.
37. Truyen L, van Waesberghe JH, van Walderveen MA et al. (1996). Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476.
38. Zivadinov R, Sepcic J, Nasuelli D et al. (2001). A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 70:773-780.